Article
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.
Expert review of hematology - 1 Mar 2018
Mangaonkar Abhishek A, Hoversten Katherine P, Gangat Naseema
Abstract excerpt
INTRODUCTION: Polycythemia Vera (PV) and Essential Thrombocythemia (ET) are the most frequent Philadelphia chromosome-negative myeloproliferative neoplasms, the other entity being myelofibrosis. Management of patients with PV and ET is fraught with difficulties as they have an inherent tendency to cause thrombotic and hemorrhagic events. There are no curative treatment options, therefore it is important that a...
Topics
- Aged
- Aged, 80 and over
- Female
- Humans
- Janus Kinase 2
- Male
- Middle Aged
- Models, Biological
- Mutation
- Polycythemia Vera
- Prognosis
- Risk Assessment